SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Cheng who wrote (342)2/8/1997 4:37:00 AM
From: Bill Harmond   of 1762
 
Don, I'm looking at the most recent Morgan Stanley report on IDPH, dated December 9, 1996, relating to the Phase III final results of C2B8, with these estimates:

CY, 1996, $(0.29)
CY, 1997, $(0.47)
CY, 1998, $ 0.60
CY, 1999, $ 1.85
CY, 2000, $ 2.60

Strong Buy rating. 12-month price target $40, derived by applying a 30 multiple and 25% discount to their CY 2000 estimate.

Hope this helps.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News